Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Foresite Capital Management IV, LLC (CIK 1704132) reported $237.1M across 7 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: PHVS ($135.0M, 56.94%), CYTK ($33.2M, 13.99%), ($20.6M, 8.67%), LYEL ($16.1M, 6.77%), RLAY ($9.9M, 4.20%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PHVS | Pharvaris N.V. | $135.0M | 56.94% | 4.8M | Hold |
| 2 | CYTK | CYTOKINETICS INC | $33.2M | 13.99% | 503,295 | Added |
| 3 | Eikon Therapeutics, Inc. | $20.6M | 8.67% | 1.9M | New | |
| 4 | LYEL | Lyell Immunopharma, Inc. | $16.1M | 6.77% | 800,399 | Hold |
| 5 | RLAY | Relay Therapeutics, Inc. | $9.9M | 4.20% | 1.0M | Hold |
| 6 | XENE | Xenon Pharmaceuticals Inc. | $9.3M | 3.92% | 160,000 | Hold |
| 7 | ALEC | Alector, Inc. | $8.4M | 3.53% | 3.9M | Hold |
| 8 | MAZE | Maze Therapeutics, Inc. | $4.7M | 1.98% | 156,901 | Trimmed |
Source: SEC Form 13F filings · as of 2026-03-31